A Study of Ivonescimab in First-Line ES-SCLC

Summary

The goal of this clinical trial is to learn if different combinations of a drug called Ivonescimab, along with chemotherapy and other investigational drugs, are safe and effective for the initial treatment of adults with extensive-stage small cell lung cancer (ES-SCLC). The main questions the study aims to answer are: * What side effects do participants experience from these combination treatments? * How well do the treatments work to shrink tumors? Researchers will compare three groups to see which combination works best. All participants will receive Ivonescimab and chemotherapy (etoposide and carboplatin). The differences are: * Group 1 will also receive an additional drug called AK117. * Group 2 will also receive a different additional drug called Cadonilimab. * Group 3 will receive Ivonescimab and chemotherapy only. Participants will: * Be assigned by chance to one of the three groups. * Undergo an initial treatment phase (about 3 months), receiving chemotherapy plus the specific study drugs for their group. * If the treatment is effective and side effects are manageable, continue with a maintenance phase using only the study drugs (without chemotherapy) for up to 2 years. * Attend regular clinic visits for check-ups, blood tests, and imaging scans (like CT scans) to see how they are responding to the treatment.

Eligibility

Inclusion Criteria:

* Histologically or cytologically confirmed extensive-stage small cell lung cancer (ES-SCLC).
* No prior systemic therapy for ES-SCLC.
* At least one measurable lesion as defined by RECIST v1.1.
* Age 18 to 75 years.
* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
* Adequate organ function.

Exclusion Criteria:

* Active or untreated central nervous system (CNS) metastases (Treated, stable brain metastases are allowed).
* History of severe hypersensitivity to monoclonal antibodies.
* Active autoimmune disease requiring systemic treatment within the past 2 years.
* Significant cardiovascular disease.
* Active hepatitis B or C, or HIV infection.
* Interstitial lung disease or non-infectious pneumonitis.
* Significant bleeding tendency or risk, including tumor invasion of major blood vessels.
* Pregnancy or lactation.
* Other active malignancies within 5 years prior to enrollment.

Conditions3

Interventions5

Related trials

• A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma — Akeso
• A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC) — Akeso
• A Study to Efficacy and Safety of SPH4336 Monotherapy or in Combination With Cadonilimab in Patients With Advanced Solid Tumors. — Shanghai Pharmaceuticals Holding Co., Ltd
• AK104 and Low-dose Radiation in Recurrent/Metastatic HNSCC After Failure of First-line Systemic Therapy — Fudan University
• AK104 in Combination With AK112 Plus Chemotherapy(SOX/XELOX) as First-line Treatment for Advanced G/GEJ Cancer — Harbin Medical University
• Cadonilimab (AK104) Plus Chemotherapy as First-line Treatment in Non-squamous Non-Small Cell Lung Cancer (NSCLC) Patients With Programmed Cell Death Ligand 1 (PD-L1) Negative — Qian Chu
• Cadonilimab Combination Regimen as First-line Treatment for HER2-expressing GC/GEJ Patients — Zhejiang Cancer Hospital
• Cadonilimab Combined With Chemotherapy as First or Second Line Treatment in Recurrent or Metastatic Triple Negative Breast Cancer — Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Browse More Trials